These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 16094296

  • 1. In vitro investigation of antifungal activities of phenotypic variation Candida albicans strains against fluconazole, itraconazole and voriconazole.
    Cetinkaya Z, Kiraz N.
    Nihon Ishinkin Gakkai Zasshi; 2005; 46(3):197-201. PubMed ID: 16094296
    [Abstract] [Full Text] [Related]

  • 2. Variable antifungal susceptibility of wild-type Candida albicans phenotypes from neutropenic hosts.
    Velegraki A, Papalambrou D, Soremi S, Legakis NJ.
    Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):854-60. PubMed ID: 8997556
    [Abstract] [Full Text] [Related]

  • 3. Phenotypic variation and antifungal susceptibility patterns of Candida albicans strains isolated from neutropenic patients.
    Kiraz N, Anğ O, Akgün Y, Erturan Z.
    Mycoses; 2000 Nov; 43(3-4):119-23. PubMed ID: 10907341
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
    Cuenca-Estrella M, Díaz-Guerra TM, Mellado E, Monzón A, Rodríguez-Tudela JL.
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
    [Abstract] [Full Text] [Related]

  • 5. Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.
    Lee JK, Peters D, Obias AA, Noskin GA, Peterson LR.
    Int J Antimicrob Agents; 2000 Nov; 16(3):205-9. PubMed ID: 11091037
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM, Reviákina V, Dolande M, Selgrad S.
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro activity of voriconazole against Candida species.
    Kauffman CA, Zarins LT.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):297-300. PubMed ID: 9597390
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
    Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC.
    Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Colorimetric method for susceptibility testing of voriconazole and other triazoles against Candida species.
    Kauffman CA, Zarins LT.
    Mycoses; 1999 Aug; 42(9-10):539-42. PubMed ID: 10592697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.